Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 4, Pages 1794
Publisher
MDPI AG
Online
2021-02-13
DOI
10.3390/ijms22041794
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical and Experimental Evaluation of Diagnostic Significance of Alpha-Fetoprotein and Osteopontin at the Early Stage of Hepatocellular Cancer
- (2021) Z. Macek-Jilkova et al. BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE
- Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma
- (2020) Gustavo Ferrín et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Molecular therapies for HCC: Looking outside the box
- (2020) Sandrine Faivre et al. JOURNAL OF HEPATOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Spotlight on AKT: Current Therapeutic Challenges
- (2020) Ina Landel et al. ACS Medicinal Chemistry Letters
- Modulating the Crosstalk between the Tumor and Its Microenvironment Using RNA Interference: A Treatment Strategy for Hepatocellular Carcinoma
- (2020) Mariam Mroweh et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A combination of AZD5363 and FH5363 induces lethal autophagy in transformed hepatocytes
- (2020) Tapas Patra et al. Cell Death & Disease
- Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer
- (2020) Douglas K. Marks et al. Frontiers in Oncology
- Hepatocellular carcinoma: old friends and new tricks
- (2020) Eunsun Kim et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- Akt-1 and Akt-2 Differentially Regulate the Development of Experimental Autoimmune Encephalomyelitis by Controlling Proliferation of Thymus-Derived Regulatory T Cells
- (2019) Song Ouyang et al. JOURNAL OF IMMUNOLOGY
- The mTORC 2‐Akt cascade is crucial for c‐Myc to promote hepatocarcinogenesis in mice and men
- (2019) Zhong Xu et al. HEPATOLOGY
- Mechanisms of hepatocellular carcinoma progression
- (2019) Olorunseun O Ogunwobi et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors
- (2019) Toshihiko Doi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Akt3-Mediated Protection Against Inflammatory Demyelinating Disease
- (2019) Juwen C. DuBois et al. Frontiers in Immunology
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017
- (2019) et al. JAMA Oncology
- Animal Models of Hepatocellular Carcinoma: The Role of Immune System and Tumor Microenvironment
- (2019) Zuzana Macek Jilkova et al. Cancers
- Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
- (2019) Zuzana Macek Jilkova et al. Cancers
- A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK
- (2018) Emma Dean et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma
- (2018) Zuzana Macek Jilkova et al. Oncotarget
- PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity
- (2018) Larissa S. Carnevalli et al. Journal for ImmunoTherapy of Cancer
- Effect of novel AKT inhibitor ARQ 751 as single agent and its combination with sorafenib on hepatocellular carcinoma in a cirrhotic rat model
- (2017) K. Keerthi et al. JOURNAL OF HEPATOLOGY
- Akt Signaling Pathway in Macrophage Activation and M1/M2 Polarization
- (2017) Eleni Vergadi et al. JOURNAL OF IMMUNOLOGY
- Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma
- (2017) Gaël S. Roth et al. MOLECULAR CANCER THERAPEUTICS
- Infiltrating mast cells promote renal cell carcinoma angiogenesis by modulating PI3K→AKT→GSK3β→AM signaling
- (2017) Y Chen et al. ONCOGENE
- Maximising the potential of AKT inhibitors as anti-cancer treatments
- (2017) Jessica S. Brown et al. PHARMACOLOGY & THERAPEUTICS
- STAT3 promotes the proliferation and migration of hepatocellular carcinoma cells by regulating AKT2
- (2017) Yi Xie et al. Oncology Letters
- Aldose reductase interacts with AKT1 to augment hepatic AKT/ mTOR signaling and promote hepatocarcinogenesis
- (2017) Jia-Xing Zhao et al. Oncotarget
- Impact of Metabolism in on T-Cell Differentiation and Function and Cross Talk with Tumor Microenvironment
- (2017) Soumaya Kouidhi et al. Frontiers in Immunology
- Spontaneous Hepatocellular Carcinoma after the Combined Deletion of Akt Isoforms
- (2016) Qi Wang et al. CANCER CELL
- Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib
- (2016) Shao-Lai Zhou et al. GASTROENTEROLOGY
- Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade
- (2016) Chunmei Wang et al. LIVER INTERNATIONAL
- Asymmetric inheritance of mTORC1 kinase activity during division dictates CD8+ T cell differentiation
- (2016) Kristen N Pollizzi et al. NATURE IMMUNOLOGY
- A novel AKT inhibitor, AZD5363, inhibits phosphorylation of AKT downstream molecules, and activates phosphorylation of mTOR and SMG-1 dependent on the liver cancer cell type
- (2016) YUNCHENG ZHANG et al. Oncology Letters
- Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
- (2016) K. Okkenhaug et al. Cancer Discovery
- Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
- (2015) GEORGE MIHAI NITULESCU et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- miR-582-5p inhibits proliferation of hepatocellular carcinoma by targeting CDK1 and AKT3
- (2015) Yi Zhang et al. TUMOR BIOLOGY
- Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer
- (2015) Daniel H. Ahn et al. Scientific Reports
- SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice
- (2015) Salvatore Delogu et al. Oncotarget
- MK2206 inhibits hepatocellular carcinoma cellular proliferation via induction of apoptosis and cell cycle arrest
- (2014) J.M. Wilson et al. JOURNAL OF SURGICAL RESEARCH
- Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma
- (2014) B. Zhai et al. MOLECULAR CANCER THERAPEUTICS
- MicroRNA-144 suppresses tumorigenesis of hepatocellular carcinoma by targeting AKT3
- (2014) YING MA et al. Molecular Medicine Reports
- Selective Inhibition of Regulatory T Cells by Targeting the PI3K-Akt Pathway
- (2014) R. Abu-Eid et al. Cancer Immunology Research
- Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
- (2013) J. Lin et al. CLINICAL CANCER RESEARCH
- Rapamycin unbalances the polarization of human macrophages to M1
- (2013) Alessia Mercalli et al. IMMUNOLOGY
- Genetics of hepatocellular carcinoma: The next generation
- (2013) Jean-Charles Nault et al. JOURNAL OF HEPATOLOGY
- Identification of AKT kinases as unfavorable prognostic factors for hepatocellular carcinoma by a combination of expression profile, interaction network analysis and clinical validation
- (2013) Yanqiong Zhang et al. Molecular BioSystems
- Crosstalk of Ras and Rho: activation of RhoA abates Kras-induced liver tumorigenesis in transgenic zebrafish models
- (2013) T W Chew et al. ONCOGENE
- SMAD-PI3K-Akt-mTOR Pathway Mediates BMP-7 Polarization of Monocytes into M2 Macrophages
- (2013) Crystal Rocher et al. PLoS One
- HS-173, a Novel PI3K Inhibitor, Attenuates the Activation of Hepatic Stellate Cells in Liver Fibrosis
- (2013) Mi Kwon Son et al. Scientific Reports
- The emerging multiple roles of nuclear Akt
- (2012) Alberto M. Martelli et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- mTOR, metabolism, and the regulation of T-cell differentiation and function
- (2012) Adam T. Waickman et al. IMMUNOLOGICAL REVIEWS
- Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
- (2012) B. R. Davies et al. MOLECULAR CANCER THERAPEUTICS
- Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization
- (2012) A. Arranz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Akt kinases: Isoform specificity in metabolism and cancer
- (2011) Eva Gonzalez et al. CELL CYCLE
- TOR in the immune system
- (2011) Koichi Araki et al. CURRENT OPINION IN CELL BIOLOGY
- The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2
- (2011) Greg M Delgoffe et al. NATURE IMMUNOLOGY
- Wnt/β-catenin signaling regulates MAPK and Akt1 expression and growth of hepatocellular carcinoma cells
- (2011) X. WANG et al. NEOPLASMA
- Akt isoforms differentially regulate neutrophil functions
- (2010) J. Chen et al. BLOOD
- Role of the mTOR Pathway in LPS-Activated Monocytes: Influence of Hypertonic Saline
- (2010) Valérie Schaeffer et al. JOURNAL OF SURGICAL RESEARCH
- The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications
- (2008) T Weichhart et al. ANNALS OF THE RHEUMATIC DISEASES
- Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises
- (2008) Timothy A Yap et al. CURRENT OPINION IN PHARMACOLOGY
- Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking
- (2008) Linda V Sinclair et al. NATURE IMMUNOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection
- (2007) Klaus Juergen Schmitz et al. JOURNAL OF HEPATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search